Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2016 Feb;16(2):121-6.
doi: 10.1038/nrc.2016.2.

Acquired resistance to immunotherapy and future challenges

Nicholas P Restifo  1 , Mark J Smyth  2 , Alexandra Snyder  3
Affiliations

Acquired resistance to immunotherapy and future challenges

Nicholas P Restifo et al. Nat Rev Cancer. 2016 Feb.

Abstract

Advances in immunotherapy have resulted in remarkable clinical responses in some patients. However, one of the biggest challenges in cancer therapeutics is the development of resistant disease and disease progression on or after therapy. Given that many patients have now received various types of immunotherapy, we asked three scientists to give their views on the current evidence for whether acquired resistance to immunotherapy exists in patients and the future challenges posed by immunotherapy.

PubMed Disclaimer

Conflict of interest statement

Competing interests statement

The authors declare competing interests: see Web version for details.

References

    1. Restifo NP, Dudley ME & Rosenberg SA Adoptive immunotherapy for cancer: harnessing the T cell response. Nat. Rev. Immunol. 12, 269–281 (2012). - PMC - PubMed
    1. Khong HT & Restifo NP Natural selection of tumor variants in the generation of “tumor escape” phenotypes. Nat. Immunol. 3, 999–1005 (2002). - PMC - PubMed
    1. Restifo NP et al. Loss of functional beta2-microglobulin in metastatic melanomas from five patients receiving immunotherapy. J. Natl Cancer Inst. 88, 100–108 (1996). - PMC - PubMed
    1. Pardoll D Cancer and the immune system: basic concepts and targets for intervention. Semin. Oncol. 42, 523–538 (2015). - PMC - PubMed
    1. Palmer DC et al. Effective tumor treatment targeting a melanoma/melanocyte-associated antigen triggers severe ocular autoimmunity. Proc. Natl Acad. Sci. USA 105, 8061–8066 (2008). - PMC - PubMed